Xu Binghe

Research areas: Personalized precision treatment for breast cancer and development of new anticancer drugs; clinical, applied basic and translational research on breast cancer.

Cutting-edge technologies: Established a new method for personalized breast cancer screening, significantly improving early detection rates; pioneered a new field of personalized treatment based on molecular subtyping. Led the development of 19 guidelines, including the National Health Commission's "Guidelines for Rational Drug Use in Breast Cancer" and "Standardized Guidelines for Breast Cancer Screening, Early Diagnosis and Treatment."

Areas of expertise: Personalized precision treatment for breast cancer, comprehensive treatment for advanced breast cancer.

Academic Highlights and Core Values: Academician of the Chinese Academy of Engineering, Chief Physician, Tenured Professor, Doctoral Supervisor, Director of the National Clinical Research Center for New Drugs (Anti-tumor), and former Director of the Department of Internal Medicine. He has presided over 29 major projects, including the National Key Scientific and Technological Project and the National Key Research and Development Program. As the first author, he received the Second Prize of the National Science and Technology Progress Award, the Ho Leung Ho Lee Foundation Science and Technology Progress Award, and the National Innovation and Pioneering Award. He has published 43 papers (13 SCI papers), with nearly 10,000 citations. His research results have been adopted by 23 domestic and international guidelines, and he participated in the development of international breast cancer diagnosis and treatment guidelines as a core member of ESMO and ESCO. His work has increased the 5-year survival rate of breast cancer from [missing information]% to 93%, placing it among the international leaders.